Analysts at Cantor Fitzgerald assumed coverage on shares of Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) in a research note issued on Tuesday, Marketbeat Ratings reports. The brokerage set an "overweight" rating on the stock.
Separately, BTIG Research initiated coverage on shares of Zealand Pharma A/S in a report on Thursday, March 7th. They issued a "buy" rating on the stock.
View Our Latest Report on Zealand Pharma A/S
Zealand Pharma A/S Stock Performance
Shares of OTCMKTS:ZLDPF traded up $2.03 during midday trading on Tuesday, hitting $90.70. 476 shares of the stock were exchanged, compared to its average volume of 2,291. The company has a market capitalization of $4.67 billion, a PE ratio of -49.84 and a beta of 0.67. Zealand Pharma A/S has a 52-week low of $33.42 and a 52-week high of $111.44. The business's fifty day simple moving average is $92.69 and its two-hundred day simple moving average is $73.08.
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.08). The business had revenue of $3.35 million for the quarter, compared to the consensus estimate of $1.97 million. Zealand Pharma A/S had a negative net margin of 213.77% and a negative return on equity of 41.49%. As a group, equities analysts anticipate that Zealand Pharma A/S will post -2.56 EPS for the current year.
Zealand Pharma A/S Company Profile
(
Get Free Report)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Further Reading
Before you consider Zealand Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zealand Pharma A/S wasn't on the list.
While Zealand Pharma A/S currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
